An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings, and opportunity lingers for a DMT that can present an even more-favorable balance of potent and low risk. Meanwhile, the development of neuroprotective and remyelinating strategies remains a critical goal. This Unmet Need content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the treatment of RR-MS, and the current level of unmet need in this area. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.